<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1529">
  <stage>Registered</stage>
  <submitdate>16/04/2007</submitdate>
  <approvaldate>16/04/2007</approvaldate>
  <nctid>NCT00461266</nctid>
  <trial_identification>
    <studytitle>ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.</studytitle>
    <scientifictitle>A Randomized, Open Label Study to Determine the Immunological Benefits of Adding Fuzeon to an Antiretroviral Regimen in HIV-infected Fuzeon-na√Øve Patients With Sustained HIV Viral Suppression</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ML19355</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - enfuvirtide [Fuzeon]
Treatment: drugs - Antiretroviral therapy

Experimental: 1 - 

Active Comparator: 2 - 


Treatment: drugs: enfuvirtide [Fuzeon]
90mg sc bid

Treatment: drugs: Antiretroviral therapy
As prescribed

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean change in CD4 cell count from baseline</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in HIV RNA from baseline</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in HIV RNA and CD4 cell count</outcome>
      <timepoint>Weeks 24-48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation between CD4 count and HIV RNA; OIs; QoL; ADEs; SAEs.</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  adult patients, &gt;=18 years of age;

          -  documented chronic HIV infection;

          -  currently receiving a stable antiretroviral regimen;

          -  CD4 cell count &lt;250 cells/mm3;

          -  HIV RNA viral load &lt;400 copies/mL for &gt;12 months.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  prior exposure to Fuzeon;

          -  prior non-adherence to antiretroviral treatment regimens;

          -  active opportunistic infection;

          -  currently taking, or anticipated to take during the study, any immunomodulator.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/04/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>0</actualsamplesize>
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Carlton</hospital>
    <hospital> - Darlinghurst</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Miami</hospital>
    <hospital> - Perth</hospital>
    <hospital> - South Yarra</hospital>
    <hospital> - Sydney</hospital>
    <postcode> - Carlton</postcode>
    <postcode> - Darlinghurst</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Miami</postcode>
    <postcode> - Perth</postcode>
    <postcode> - South Yarra</postcode>
    <postcode> - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This 2 arm study will assess the immunological benefits of adding Fuzeon to an antiretroviral
      regimen in HIV-infected, Fuzeon-naive patients with a CD4 cell count &lt;250 cells/mm3 and an
      HIV RNA viral load &lt;400 copies/mL. Eligible patients will be randomized to receive Fuzeon
      90mg bid sc in addition to their current antiretroviral therapy, or to continue their current
      antiretroviral therapy alone. The anticipated time on study treatment is 3-12 months, and the
      target sample size is &lt;100 individuals.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00461266</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>